首页|中药天然产物治疗多囊卵巢综合征慢性炎症的研究进展

中药天然产物治疗多囊卵巢综合征慢性炎症的研究进展

扫码查看
多囊卵巢综合征(PCOS)是一种育龄期女性中常见的内分泌疾病,慢性低度炎症在该综合征发展中发挥重要作用.常用的治疗药物虽然改善患者临床症状,但PCOS仍然是一种无法治愈的生殖和代谢障碍,其病因病机尚不明确,同时也面临药物依赖性和不良反应等诸多问题.因此一些安全、有效的治疗方法仍是重要的临床需求.迄今为止,中药天然产物在纠正糖脂代谢、改善激素分泌紊乱、减弱慢性炎症和氧化应激以及调节肠道菌群和免疫功能等发面表现出较大的优势和潜力.鉴于此,文章对近年来中药天然产物生物碱、多酚和黄酮类,以及萜类和醌类干预PCOS慢性炎症作用机制进行综述,以期为中医药治疗PCOS提供参考.
Research progress on natural products of traditional Chinese medicine in treatment of polycystic ovary syndrome with chronic inflammation
Polycystic ovary syndrome(PCOS)is a common endocrine disease in women of reproductive age,of which chronic low-grade inflammation plays an important role in the development.Although therapeutic drugs commonly used improve the clinical symptoms of patients,PCOS is still an incurable reproductive and metabolic disorder.Its etiology and pathogenesis are not clear,while facing many problems such as drug dependence and adverse reaction.Therefore,several safe and effective therapeutic methods are still an important clinical demand.Up to now,natural products of traditional Chinese medicine(TCM)have demonstrated great advantages and potentials in modifying glucose and lipid metabolism,improving hormone secretion disorders,attenuating chronic inflammation and oxidative stress,as well as regulating intestinal microbiota and immune function.In view of this,the narrative article is reviewed on the mechanism of natural products of TCM,including alkaloids,polyphenols and flavonoids,as well as terpenes and quinones in intervening of PCOS with chronic inflammation in recent years in order to provide reference for clinical therapeutic approaches of PCOS with TCM.

Polycystic ovary syndrome(PCOS)Chronic inflammationMechanismNatural products of traditional Chinese medicineProgress

石百超、常惠、王宇、冯佳兴、吴效科

展开 >

黑龙江中医药大学,哈尔滨 150040

黑龙江中医药大学附属第一医院,哈尔滨 150040

多囊卵巢综合征 慢性炎症 机制 中药天然产物 进展

黑龙江省"头雁"团队-中西医结合妇科特色技术创新团队2023年中医药循证能力提升项目黑龙江省中医药学会2022-2024年度青年人才托举工程项目

LH2019H0462022-QNRC1-02

2024

中华中医药杂志
中华中医药学会

中华中医药杂志

CSTPCD北大核心
影响因子:1.135
ISSN:1673-1727
年,卷(期):2024.39(8)